BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 26186733)

  • 1. The Role of CD56 in Thyroid Fine Needle Aspiration Cytology: A Pilot Study Performed on Liquid Based Cytology.
    Bizzarro T; Martini M; Marrocco C; D'Amato D; Traini E; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM; Rossi ED
    PLoS One; 2015; 10(7):e0132939. PubMed ID: 26186733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of thyroid fine-needle aspiration cytology in the pediatric population: an institutional experience.
    Rossi ED; Straccia P; Martini M; Revelli L; Lombardi CP; Pontecorvi A; Fadda G
    Cancer Cytopathol; 2014 May; 122(5):359-67. PubMed ID: 24474727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of the cytological diagnostic accuracy of follicular thyroid lesions by the use of the Ki-67 proliferative index in addition to cytokeratin-19 and HBME-1 immunomarkers: a study of 61 cases of liquid-based FNA cytology with histological controls.
    Lacoste-Collin L; d'Aure D; Bérard E; Rouquette I; Delisle MB; Courtade-Saïdi M
    Cytopathology; 2014 Jun; 25(3):160-9. PubMed ID: 24460983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of immunocytochemical stainings for galectin-3, CD44, and HBME1 to fine-needle aspiration cytology diagnosis of papillary thyroid carcinoma.
    Das DK; Al-Waheeb SK; George SS; Haji BI; Mallik MK
    Diagn Cytopathol; 2014 Jun; 42(6):498-505. PubMed ID: 24273003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic value of HBME-1, CD56, Galectin-3 and Cytokeratin-19 in papillary thyroid carcinomas and thyroid tumors of uncertain malignant potential.
    Nechifor-Boilă A; Cătană R; Loghin A; Radu TG; Borda A
    Rom J Morphol Embryol; 2014; 55(1):49-56. PubMed ID: 24715165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin.
    Ceyran AB; Şenol S; Şimşek BÇ; Sağıroğlu J; Aydın A
    Int J Clin Exp Pathol; 2015; 8(4):3670-80. PubMed ID: 26097548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A large series of hyalinizing trabecular tumors: Cytomorphology and ancillary techniques on fine needle aspiration.
    Dell'Aquila M; Gravina C; Cocomazzi A; Capodimonti S; Musarra T; Sfregola S; Fiorentino V; Revelli L; Martini M; Fadda G; Pantanowitz L; Larocca LM; Rossi ED
    Cancer Cytopathol; 2019 Jun; 127(6):390-398. PubMed ID: 31135104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TROP-2 expression in papillary thyroid cancer: a preliminary cyto-histological study.
    Addati T; Achille G; Centrone M; Petroni S; Popescu O; Russo S; Grammatica L; Simone G
    Cytopathology; 2015 Oct; 26(5):303-11. PubMed ID: 25164548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.
    Abd-El Raouf SM; Ibrahim TR
    Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 and thyroid cytology: A possible diagnostic and prognostic marker.
    Dell'Aquila M; Granitto A; Martini M; Capodimonti S; Cocomazzi A; Musarra T; Fiorentino V; Pontecorvi A; Lombardi CP; Fadda G; Pantanowitz L; Larocca LM; Rossi ED
    Cancer Cytopathol; 2020 Mar; 128(3):177-189. PubMed ID: 31821747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical expression of HBME-1, E-cadherin, and CD56 in the differential diagnosis of thyroid nodules.
    Ozolins A; Narbuts Z; Strumfa I; Volanska G; Stepanovs K; Gardovskis J
    Medicina (Kaunas); 2012; 48(10):507-14. PubMed ID: 23324246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evaluation of miRNAs on thyroid FNAC: the promising role of miR-375 in follicular neoplasms.
    Rossi ED; Bizzarro T; Martini M; Capodimonti S; Sarti D; Cenci T; Bilotta M; Fadda G; Larocca LM
    Endocrine; 2016 Dec; 54(3):723-732. PubMed ID: 26818914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cytological diagnosis of a 'benign thyroid lesion': is it a real safe diagnosis for the patient?
    Rossi ED; Bizzarro T; Fadda G; Pontecorvi A; Bernet V; Nassar A
    Cytopathology; 2016 Jun; 27(3):168-75. PubMed ID: 26388423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultrasound Risk Assessment Combined with Molecular Markers of Galectin-3, c-MET, HBME-1 and CK19 for Diagnosis of Malignant and Benign Thyroid Nodules.
    Han RL; Wang J; Zhang FJ; Zhao N; Gao BL
    Pathol Oncol Res; 2019 Jul; 25(3):1075-1081. PubMed ID: 30361909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroid tumors of uncertain malignant potential: morphologic and imunohistochemical analysis of 29 cases.
    Nechifor-Boila A; Borda A; Sassolas G; Hafdi-Nejjari Z; Cătană R; Borson-Chazot F; Berger N; Decaussin-Petrucci M
    Pathol Res Pract; 2015 Apr; 211(4):320-5. PubMed ID: 25595997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic utility of immunohistochemical panel in various thyroid pathologies.
    Ozolins A; Narbuts Z; Strumfa I; Volanska G; Gardovskis J
    Langenbecks Arch Surg; 2010 Sep; 395(7):885-91. PubMed ID: 20640858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
    Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
    Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunocytochemistry with cytokeratin 19 and anti-human mesothelial cell antibody (HBME1) increases the diagnostic accuracy of thyroid fine-needle aspirations: preliminary report of 150 liquid-based fine-needle aspirations with histological control.
    Cochand-Priollet B; Dahan H; Laloi-Michelin M; Polivka M; Saada M; Herman P; Guillausseau PJ; Hamzi L; Poté N; Sarfati E; Wassef M; Combe H; Raulic-Raimond D; Chedin P; Medeau V; Casanova D; Kania R
    Thyroid; 2011 Oct; 21(10):1067-73. PubMed ID: 21875347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the follicular patterned thyroid lesions based on the WHO 2022 criteria with an emphasis on the grey-zone lesions.
    Misra S; Dhawan S; Badwal S; Sengupta A; Khosla A; Agarwal SK; Rao S
    Ann Diagn Pathol; 2024 Aug; 71():152282. PubMed ID: 38522359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined staining for immunohistochemical markers in the diagnosis of papillary thyroid carcinoma: improvement in the sensitivity or specificity?
    Wu G; Wang J; Zhou Z; Li T; Tang F
    J Int Med Res; 2013 Aug; 41(4):975-83. PubMed ID: 23857157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.